Abstract Background and Aims Hydralazine-isosorbide dinitrate (H-ISDN) has shown benefit in earlier randomized trials of patients with reduced left ventricular ejection fraction (LVEF) and chronic heart failure. This trial tested if H-ISDN could reduce worsening heart failure or mortality in patients with chronic heart failure with reduced ejection fraction (HFrEF) receiving contemporary treatment. Methods The Hydralazine-Isosorbide Dinitrate in Patients With Chronic Heart Failure Trial (H-HeFT) was a multicentre, randomized (1:1), double-blind, placebo-controlled trial in patients with HFrEF at 23 Danish hospitals (New York Heart Association class II–IV, elevated N-terminal pro-B-type natriuretic peptide and LVEF ≤40%). Target treatment was hydralazine 75 mg/isosorbide dinitrate 40 mg three times a day (t.i.d). The primary endpoint was a composite of hospitalization with worsening heart failure, an urgent outpatient visit resulting in intravenous/metolazone therapy for heart failure, heart transplantation, left ventricular assist device implantation, or death. Secondary endpoints included components of the primary outcome. Results Overall, 592 predominantly White patients (median age 72 years, 18% women) were randomized with a mean follow-up of 3.7 years. The primary outcome occurred in 90 of 294 patients (30.6%) in the H-ISDN group and in 91 of 298 patients (30.5%) in the placebo group [hazard ratio (HR) 0.90; 95% confidence interval (CI) 0.67–1.21; P = .48]. There were 57 deaths in the H-ISDN group vs 72 in the placebo group (HR 0.72; 95% CI 0.51–1.02); worsening heart failure events occurred in 52 vs 47 patients (HR 1.01; 95% CI 0.68–1.50). Conclusions Hydralazine-isosorbide dinitrate did not change the incidence of the composite endpoint of heart failure events or death in patients with heart failure and LVEF ≤40%.
Abstract Background Measures of left atrial (LA) function are strongly associated with atrial fibrillation (AF). Three-dimensional echocardiography (3D) enables more precise geometric assessment than conventional 2D echocardiography and may offer incremental value to standard measures. Purpose To investigate the association between 3D LA strain and AF in a high-risk population. Methods We used data from the randomized controlled LOOP study which included elderly (≥70 years) with at least one stroke risk factor (hypertension, diabetes, heart failure, or prior stroke), who were randomized to implantable loop recorder (ILR) monitoring or usual care. Participants who had an ILR implanted and underwent 3D echocardiography were included. 3D-reservoir strain (3D-LASr), conduit strain (3D-LAScd), and contraction strain (3D-LASct) was quantified. The endpoints were incident device-detected AF ≥6 minutes and ≥24 hours. Associations between strain and AF were evaluated using Cox regression. Multivariable analysis was adjusted for the CHARGE-AF risk score (age, height, weight, blood pressure, smoking, hypertension, diabetes, congestive heart failure, history of myocardial infarction). Incremental prognostic value was assessed using C-statistics. Results The study included 819 participants, all underwent 3D echocardiography and had an ILR implanted. Mean age was 74.2±3.9 years, 638 (53%) were male. During a median follow-up time of 4.3 years (IQR 2.2-5.5 years), 236 (28.8%) participants had device-detected AF ≥6 minutes, and 34 (4.2%) AF ≥24 hours. Mean 3D-LA 3D-LASr was 20.7%, 3D-LAScd was 8.9%, and 3D-LASct was 11.9%. In univariable analysis 3D-LASr (HR 1.03 (95% CI 1.01-1.05); p=0.015, per 1 % decrease) and 3D-LASct (HR 1.05 (95% CI 1.02-1.07); p<0.001), per 1 % decrease), but not 3D-LAScd (HR 0.98 (95% CI 0.96-1.01); p=0.15, per 1% decrease) were associated AF≥6 minutes (Figure 1). These findings persisted after multivariable adjustment: 3D-LASr (HR 1.03 (95% CI 1.00-1.05); p=0.017, per 1% decrease) and 3D-LASct (HR 1.05 (95% CI 1.02-1.07); p<0.001, per 1% decrease). Similar findings were observed for ≥24-hour device detected AF in unadjusted analysis (Figure 2), and after multivariable adjustment (3D-LASr: HR 1.12 (95% CI 1.05-1.18); p=0.001, per 1% decrease; 3D-LASct: HR 1.16 (95% CI 1.08-1.24); p<0.001, per 1% decrease). When the continuous 3D variables were added to the CHARGE-AF score, 3D-LASct increased the C-statistic for both AF≥6 minutes (change in C-statistic 0.528 to 0.584, p =0.011) and AF≥24 hours (0.61 to 0.71, p =0.042) whereas 3D-LASr did not. Given association between 3D-LASr and outcomes were non-linear (p for nonlinearity<0.05), further studies are needed to evaluate whether 3D-LASr adds incremental value. Conclusion In a high-risk population, 3D reservoir and contraction strain were independently associated with device-detected AF, and 3D contraction strain adds incremental value to clinical risk scores.
The aim was to characterize longitudinal JAK2V617F (JAK2) variant allele frequency (VAF) trajectories in individuals without MPN undergoing active surveillance, and to assess whether MPN can be detected at an earlier stage, resulting in lower clonal burden and less bone marrow fibrosis. In the Danish General Suburban Population Study (N=19,958, 2010-2013), we used retrospective measurement of JAK2 on biobanked samples in 2016-2017 and identified 92 JAK2-positive individuals with VAF≥1% that were without MPN at baseline in 2010-2013. Of these, 20 were diagnosed with MPN by clinical referral between 2010-2018. The remaining 72 were reinvited for active MPN surveillance (2018-2026), of whom 61 are included in the present study. Longitudinal JAK2 VAF was quantified using droplet digital PCR, and mixed-effects models were used to estimate clonal growth and blood cell trajectories. Median follow-up to MPN diagnosis was 7.4 years. Referral-diagnosed MPN cases exhibited a relative clonal growth rate of 34.3% per year (p<0.001). Among the 61 undergoing surveillance, 20 were diagnosed with MPN, exhibiting a relative clonal growth rate of 12.7% per year (p=0.003), whereas the remaining 41 did not develop MPN nor showed VAF progression (p=0.628). Within-individual and between-individual variance in VAF was 4.9% and 95.1%, respectively. Platelet counts increased 10.3×10⁹/L/year for surveillance-detected MPN and 44.5×10⁹/L/year for referral-diagnosed MPN. Surveillance-detected MPN had lower VAF at diagnosis (median 13.0% vs 41.3%) and less bone marrow fibrosis (grade 0: 80% vs 15%) than referral-diagnosed MPN. Active surveillance detects MPN with lower clonal burden and less bone marrow fibrosis.
Objective: To evaluate the vaccine effectiveness (VE) of RSVpreF compared with no vaccination among adults with and without neurological or cerebrovascular disease. Background: Adults with neurological or cerebrovascular disease have an elevated risk of severe outcomes following respiratory syncytial virus infection. Whether vaccination with an RSV prefusion F protein-based vaccine reduces respiratory and cardiovascular outcomes in this population is uncertain. Design/methods: We conducted a prespecified secondary analysis of the DAN-RSV trial, a pragmatic, open-label, individually randomized controlled trial in Denmark. Adults aged 60 years or older were randomized 1:1 to RSVpreF vaccination or no vaccine. Outcomes were obtained from nationwide health registries. The primary outcome was hospitalization for RSV-related respiratory tract disease (RTD). VE was estimated as one minus the incidence rate ratio, expressed as percentage. Results: In total, 65,642 were randomized to RSVpreF and 65,634 to no vaccine. The incidence rate of almost all outcomes was higher among the 7,223 participants with neurological/cerebrovascular disease as compared to the 124,059 without. VE for RSV-related RTD hospitalization was 100% (0 vs 1 event; 95% CI; not calculable; number needed to vaccinate (NNV)=1506) among participants with neurological/cerebrovascular disease and 82.4% (95% CI, 39.0–96.7; NNV=1844) among those without. Comparing those with neurological/cerebrovascular disease to those without, VE for all-cause RTD hospitalization was 28.1% (95% CI -18.0-58.8; NNV 141) vs 13.5% (95% CI -2.6-27.0%; NNV 643), VE for all-cause cardiorespiratory hospitalization was 17.4% (95% CI -10.6-41.1; NNV=92) vs 8.9% (95% CI -1.7-18.2; NNV=412), VE for stroke 43.1 (95% CI -33.7-78.3; NNV=218) vs 15.0% (95% CI -17.4-38.4%; NNV=1981). The effect of vaccination was consistent regardless of neurological/cerebrovascular disease status (P interaction for all>0.05). Neurological outcomes were neutral for neurological hospitalizations [VE 14.5% (95% CI, -10.0 to 33.9); NNV=1345] and all-cause dementia favored RSVpreF [VE 20.7% (95% CI, -12.2 to 44.4)]. For Alzheimer’s dementia, treatment effect differed by baseline disease status (p=0.04), with reduced new-onset Alzheimer’s dementia among participants without baseline disease [VE 57.9% (95% CI, -0.8 to 84.1); P=0.041]. Conclusions: RSVpreF vaccination showed similar VE across subgroups. For all-cause outcomes, estimated NNV trended lower for those with underlying neurological or cerebrovascular disease due to a combination of higher VE point estimates and higher underlying rates of disease. RSVpreF vaccination was not associated with an increased risk of neurological hospitalizations, supporting neurological safety, while dementia outcomes showed a trend towards favoring RSVpreF vaccination.